Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study

Award Number: R01NS080821
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2013
PERIOD OF PERFORMANCE END DATE: 07/31/2015

Group Awards By:

View Award Description

CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study - DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a common chronic neurological disorder affecting approximately 1 in 1000 Caucasians, particularly persons of Northern European origin who reside in temperate climates. Although there is still no cure for MS, several drugs can delay the progression of clinical worsening of patients with relapsing-remitting MS (RRMS). However, no treatment is available for primary and secondary progressive MS (PPMS and SPMS). For more than 10 years, we have focused our research on the role of CD24 in MS. Our studies in animal models established that the primary function of CD24 is to regulate the persistence of autoreactive T cells after they have reached the CNS. The significance of this checkpoint for MS is supported by genetic studies that demonstrate that a polymorphism of CD24 controls risk and/or progression of MS. Based on these novel observations, we have devoted more than 10 years of effort to develop therapeutics that target CD24 for the treatment of MS. We have completed manufacture, efficacy, and toxicity studies in animal models of EAE and in non-human primates. We have recently received FDA approval of our IND for a first-in- human study. Here we propose a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety, tolerability, immunogenicity and pharmacokinetics of CD24Fc in healthy adult subjects. The phase I studies will be carried out by one of the most respected CROs in the nation with strong track record in clinical drug testing. The phase I studies proposed herein will provide crucial safety information for a go-no-go decision of the phase II studies. The human PK and immunogenicity data will be valuable for the design of phase II studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $534,084 )
2014	2014	ONCOIMMUNE INC	333 PARKLAND PLAZA	ANN ARBOR	MI	48103	WASHTENAW	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	7/29/2014	NON-COMPETING CONTINUATION	$534,084
														Subtotal = $534,084

Issue Date FY: 2013 ( Subtotal = $546,203 )
2013	2013	ONCOIMMUNE INC	333 PARKLAND PLAZA	ANN ARBOR	MI	48103	WASHTENAW	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	8/5/2013	NEW	$546,203
														Subtotal = $546,203

Grand Total All Awards = $1,080,287

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study

Award Number: R01NS080821

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2013

PERIOD OF PERFORMANCE END DATE: 07/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer